.
MergerLinks Header Logo

Announced

Completed

Senti Biosciences went public via merger with Dynamics Special Purpose in a $601m deal.

Financials

Edit Data
Transaction Value£453m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Private Equity

Biotechnology

biotechnology company

United States

De-SPAC

Friendly

Domestic

Majority

Acquisition

Merger

Private

Reverse Takeover

Single Bidder

Completed

Synopsis

Edit

Senti Biosciences, a company developing cancer therapies using a new programmable biology platform, went public via merger with Dynamics Special Purpose, a special purpose acquisition company, in a $601m deal. The deal involved a $66m financing from institutional investors including 8VC, Amgen Ventures, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, LifeForce Capital, NEA, Parker Institute for Cancer Immunotherapy, and T. Rowe Price. "Humans have always sought medicines that can treat illnesses with more precision, efficacy, and safety. However, existing drugs are still unable to match the complexity of many diseases, such as cancer and beyond. With recent advances in synthetic biology, computation, and massive biological data generation, I believe that we have a unique opportunity to engineer intelligent cell and gene therapies that directly tackle the heterogeneity and dynamic nature of disease, which have the potential to fundamentally transform our therapeutic arsenal," Tim Lu, Senti Bio CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US